X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Novo Nordisk Insulin Cartridge

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Novo Nordisk is upgrading the insulin production plant at its facility in Chartres, Eure-et-Loir region, France. The Danish company is one of the largest producers of insulin products in the world; the company is responsible for over one third of all insulin production.

The upgrade to the Chartres plant, which has been producing insulin since 1959, is in response to a World Health Organisation (WHO) projection of an increase in the number of diabetes cases expected by 2030. The WHO predicts an increase from 177 million cases in the present day to 370 million in 2030.

The new plant expansion is requiring an investment of €218m.

The plant will be designed to increase the production capacity of insulin doses and also to increase the volume of production of the Novo Nordisk Flexpen, an injection-less pen dosage system that makes the management of diabetic medication much easier.

The expansion will potentially be able to serve the whole European market and parts of Middle East and Africa.

Insulin cartridge production plant

The plant at Chartres has previously undergone an expansion program initiated in September 1996 and inaugurated in the final quarter of 1999. The total cost of this was FFr450m ($64.3m) and the insulin cartridge production was increased to 60 million per year. This further plant expansion began in 2003.

The upgrade includes an additional filling line and two new assembly and packaging lines. This will double the production of insulin cartridge doses from 92 million per year at present to over 180 million units at full production. Production at Chartres has increased by 60% since 2005. Phase one of the expansion, which included the installation of a new Flexpen assembly area, was completed in September 2005.

The upgrade is in response to a WHO projection of an increase in the number of diabetes cases expected by 2030.”

Contractors

The contract for the engineering and the project management of the expansion at the Chartres plant has been awarded to Technip in conjunction with Novo Nordisk Engineering. The expansion is being carried out in two phases.

The first phase was completely managed by Technip and included the revamp and expansion of the existing insulin filling line, a new assembly and packaging workshop for insulin injection pens and a new state-of-the-art central heating and climate control system.

The first phase, completed by the first half of 2005, was carried out by the Paris engineering centre of Technip. It required over 70,000 engineering hours to complete within the timescale. The second phase of the expansion is being managed by Technip and Novo Nordisk Engineering in a joint effort and will include the installation and validation of a new filling line for Penfill and two new assembly and packaging lines. The filling line, scheduled to be commissioned in 2011, will expand the plant’s capacity significantly.

Further insulin production plant products

Novo Nordisk has a number of products in development which the plant will be able to produce. These include the NovoMix range of pre-mixed insulin analogues and Novo Rapid, for which the company has obtained European marketing approval as a diabetes treatment. Novo Rapid is an extremely fast-acting drug, and thus allows users much greater freedom.

“Novo Nordisk is developing an inhalable form of insulin.”

Novo Nordisk is also developing an inhalable form of insulin in conjunction with Aradigm. The new drug form, NN-1998, will use Aradigm’s AERx delivery technology and is currently in pivotal phase III clinical trials. This inhalable form of insulin will be an even greater step towards diabetic medication convenience and patient freedom.

Tags: Europe
Previous Post

Kemwell Pharmaceutical Manufacturing Facility

Next Post

Quintiles Drug Research Unit

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Gilead's drug remdesivir gets US FDA's emergency use authorisation for COVID-19
Europe

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

4th May 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Quintiles Drug Research Unit

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In